Holen Sie sich die Stockscreener-App
26.93
3.38%
0.88
Handel nachbörslich:
26.78
-0.15
-0.56%
Schlusskurs vom Vortag:
$26.05
Offen:
$26.285
24-Stunden-Volumen:
10.09M
Relative Volume:
0.97
Marktkapitalisierung:
$10.41B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-3.0848
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
+0.79%
1M Leistung:
-3.20%
6M Leistung:
-37.46%
1J Leistung:
-81.79%
1-Tages-Spanne:
$25.76
$27.15
1-Wochen-Bereich:
$25.55
$27.85
52-Wochen-Spanne:
$23.15
$158.82
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.93 | 10.33B | 3.14B | -3.36B | -4.03B | -8.73 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
HHS cancels Moderna’s $590 million contract for bird flu vaccine - WyomingNews.com
Trump administration pulls bird flu, other vaccine funding awarded to Moderna - CBS News
HHS cancels Moderna bird flu vaccine contract - The Iola Register
Moderna at Bernstein Conference: Strategic Diversification Plans - Investing.com
Is Moderna Stock A Sell After RFK Jr. Yanks Its Bird Flu Vaccine Funding? - Investor's Business Daily
HHS terminates Moderna contract to develop bird flu vaccine - BioPharma Dive
HHS terminates Moderna’s funding for bird flu vaccine, calls mRNA 'under-tested' - The Business Journals
Transcript : Moderna, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 10 - marketscreener.com
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot - Yahoo Finance
Moderna Is Imperiled by Kennedy’s Health Department. It May Run Out of Cash. - Barron's
Trump administration cancels $766 million Moderna contract to fight future pandemics, including bird flu - NBC News
U.S. Ends $600M Moderna Bird Flu Vaccine Contract - HomeTown Register
HHS cancels $590 million contract with Moderna for bird flu vaccine - WAPT
HHS, led by vaccine skeptic RFK Jr., cancels contract to fight flu viruses - LiveNOW from FOX
Moderna: positive results for H5 avian influenza vaccine - marketscreener.com
Moderna (MRNA) Faces Uncertainty After $766M Contract Termination - GuruFocus
Trump administration cancels $766 million contract with Moderna to develop vaccine against pandemic flu viruses - Fortune
Moderna Loses $760M+ Government Bird Flu Contract as Vaccine Uncertainties Mount - BioSpace
Big blow to Moderna vaccine projects as Trump cancels over $700 million funding - The Economic Times
Trump administration yanks Moderna's bird flu vaccine research funding even as company reports promising test results - CBS News
Moderna stock steady as HHS ends vaccine contract (MRNA:NASDAQ) - Seeking Alpha
Trump Team Pulls $766M Funding Plug on Moderna’s Bird Flu Vaccine - TipRanks
Moderna’s H5 avian flu vaccine shows promise in early trial By Investing.com - Investing.com South Africa
US cancels $766 million pandemic flu vaccine support to Moderna - India Today
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort - Benzinga
Trump admin cancels $766m Moderna contract to fight pandemic flu - MSN
US cancels $590 million contract with Moderna for bird flu shot - Medical Xpress
US cancels $700m in funding for Moderna's bird flu vaccine - The Express Tribune
Trump administration cancels $766 million Moderna contract to fight pandemic flu - MSN
Moderna Says Investigational Influenza Vaccine Boosts Immunity; US Government to Terminate Funding - marketscreener.com
US cancels more than $700 million funding for Moderna bird flu vaccine - Reuters
Woodline Partners LP Purchases 10,968 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
U.S. Government cancels $766 million Moderna contract to fight pandemic flu - The Hindu
Moderna, Inc. (MRNA) Reports Strong H5 Avian Flu Vaccine Data Despite HHS Funding Cut - Yahoo Finance
Moderna Stock Drops On HHS Funding Termination For Pandemic Flu Vaccine; Retail Turns Bearish By Stocktwits - Investing.com India
Trump administration cancels $766 million contract to develop mRNA-based flu vaccines - FOX 13 News Utah
Trump administration cuts $766 million in funding to Moderna for bird flu, pandemic vaccine projects - Times of India
Trump's HHS cancels Moderna's $590M bird flu vaccine award - Axios
Moderna Announces Update on Investigational Pandemic Influenza Program - USA Today
US cancels more $700 million funding for Moderna bird flu vaccine - WTVB
Lazard Asset Management LLC Has $110,000 Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Reports Positive Interim Results for H5 Flu Vaccine Trial | MRNA Stock News - GuruFocus
HHS Cancels Moderna’s $590 Million Contract for Bird Flu Vaccine - Bloomberg
Moderna (MRNA) Faces Contract Cancellation by U.S. Health Department | MRNA Stock News - GuruFocus
Moderna Announces Update on Investigational Pandemic Influenza P - GuruFocus
Moderna’s H5 avian flu vaccine shows promise in early trial - Investing.com
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):